Evidence map›Paper›PMID 36966162›Full record

ArticleScientific reports2023

The oncogenic properties of the EWSR1::CREM fusion gene are associated with polyamine metabolism.

Heidi Kaprio, Arafat Siddiqui, Lotta Saustila, Vanina D Heuser, Maria Gardberg

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. [High expression of CREM is associated with poor prognosis in gastric cancer patients].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Heidi KaprioDepartment of Pathology, Turku University Hospital, Kiinamyllynkatu 10 D, Turku, Finland. heidi.kaprio@utu.fi.
Arafat SiddiquiDepartment of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland.
Lotta SaustilaInstitute of Biomedicine, University of Turku, Turku, Finland.
Vanina D HeuserDepartment of Pathology, Turku University Hospital, Kiinamyllynkatu 10 D, Turku, Finland.
Maria GardbergDepartment of Pathology, Turku University Hospital, Kiinamyllynkatu 10 D, Turku, Finland.
Turku University Hospital · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EWSR1::CREM fusion gene, caused by a chromosomal translocation t(10;22)(p11;q12), has been discovered in divergent malignancies, ranging from low-grade to highly malignant cancers. The translocation gives rise to a chimeric protein, EWSR1::CREM. The molecular mechanisms behind the oncogenic properties of the EWSR1::CREM protein have not previously been systematically characterized. In this study, we performed transcriptional profiling of the melanoma cell line CHL-1, with depletion of endogenous EWSR1::CREM protein using siRNA mediated knockdown. We found that the expression of 712 genes was altered (Log2 fold-change ≥ 2). We performed pathway analysis to identify EWSR1::CREM mediated pathways and cell studies to examine functional differences brought upon by the knockdown. Altered pathways involved cell cycle and proliferation, this was further validated by the cell studies where cell migration was affected as well. Among the target genes with the greatest downregulation, we discovered ODC1-a well-established oncogenic enzyme that can be pharmacologically inhibited and is essential for polyamine synthesis. We found that the main effects seen upon EWSR1::CREM knockdown can be reproduced by directly silencing ODC1 expression. These findings provide novel insights into pathogenesis of tumors harboring a EWSR1::CREM fusion gene, hopefully facilitating the development of novel therapeutic strategies.

Indexed as

PolyaminesTranslocation, GeneticCyclic AMP Response Element ModulatorGene FusionHumansOncogene Proteins, FusionRNA-Binding Protein EWSCREM protein, humanCyclic AMP Response Element ModulatorEWSR1 protein, humanOncogene Proteins, FusionPolyaminesRNA-Binding Protein EWS

Identifiers

PMID36966162
PMCPMC10039922
OpenAlexW4360938472

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read35
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.